- Hong Kong
- /
- Healthcare Services
- /
- SEHK:6078
Why We're Not Concerned About Hygeia Healthcare Holdings Co., Limited's (HKG:6078) Share Price
There wouldn't be many who think Hygeia Healthcare Holdings Co., Limited's (HKG:6078) price-to-earnings (or "P/E") ratio of 14x is worth a mention when the median P/E in Hong Kong is similar at about 12x. While this might not raise any eyebrows, if the P/E ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
While the market has experienced earnings growth lately, Hygeia Healthcare Holdings' earnings have gone into reverse gear, which is not great. It might be that many expect the dour earnings performance to strengthen positively, which has kept the P/E from falling. If not, then existing shareholders may be a little nervous about the viability of the share price.
Check out our latest analysis for Hygeia Healthcare Holdings
Does Growth Match The P/E?
There's an inherent assumption that a company should be matching the market for P/E ratios like Hygeia Healthcare Holdings' to be considered reasonable.
Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 36%. This means it has also seen a slide in earnings over the longer-term as EPS is down 1.7% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.
Looking ahead now, EPS is anticipated to climb by 16% per annum during the coming three years according to the analysts following the company. That's shaping up to be similar to the 14% per year growth forecast for the broader market.
In light of this, it's understandable that Hygeia Healthcare Holdings' P/E sits in line with the majority of other companies. Apparently shareholders are comfortable to simply hold on while the company is keeping a low profile.
The Final Word
It's argued the price-to-earnings ratio is an inferior measure of value within certain industries, but it can be a powerful business sentiment indicator.
As we suspected, our examination of Hygeia Healthcare Holdings' analyst forecasts revealed that its market-matching earnings outlook is contributing to its current P/E. Right now shareholders are comfortable with the P/E as they are quite confident future earnings won't throw up any surprises. It's hard to see the share price moving strongly in either direction in the near future under these circumstances.
The company's balance sheet is another key area for risk analysis. Take a look at our free balance sheet analysis for Hygeia Healthcare Holdings with six simple checks on some of these key factors.
If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
Valuation is complex, but we're here to simplify it.
Discover if Hygeia Healthcare Holdings might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SEHK:6078
Hygeia Healthcare Holdings
Offers oncology healthcare services in the People's Republic of China.
Adequate balance sheet with moderate growth potential.
Market Insights
Weekly Picks

The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
NVIDIA will see a profit margin surge of 55% in the next 5 years
Bambuser is today the only listed company in Europe that simultaneously possesses an 85% gross margin, proprietary AI infrastructure for the

Constellium jet another cyclical aluminum processor, or a mispriced aluminum platform?
Recently Updated Narratives
TROPHY GAMES Development Will See Revenue Rise by 22% in the Next 3 Years
NVIDIA will see a profit margin surge of 55% in the next 5 years
Springer REE deposit valuation
Popular Narratives

Everyone's Terrified Microsoft Will Keep Spending. I'm Terrified They'll Stop.

The academically fascinating Tesla
